(917) 985-9186
Treatment-resistant depression describes depression that has not responded adequately to appropriate treatment trials. Definitions can differ by guideline, study and insurer.
A TRD review reconstructs which treatments were taken at an adequate dose and duration, whether they were taken regularly and why they ended. It also checks the diagnosis, bipolar symptoms, sleep, substances, medical contributors and safety. The next step may be optimization, switching, augmentation, psychotherapy or a specialist advanced-treatment assessment. Spravato, off-label IV ketamine, ECT and TMS are distinct options, not one interchangeable pathway. Clinical suitability and actual service availability must be established separately. No listed option is automatically the only treatment left.
Treatment-resistant depression describes depression that has not responded adequately to appropriate treatment trials. Definitions can differ by guideline, study and insurer. In many settings, the term involves inadequate response to at least two antidepressant trials at an adequate dose and duration. A careful review is more useful than a medicine count alone: it helps explain what was tried, why it did not help and which next step fits the person.
Persistent depression can have several contributors. The original diagnosis, bipolar symptoms, sleep, substance use, medical illness, side effects and difficulty taking treatment all deserve review. Nonresponse does not mean that a person has failed. Different treatment options act through medicines, psychotherapy or brain stimulation, and more than one part of the plan may be needed.
Bring names, doses and dates of previous treatments, including whether they were taken regularly, caused side effects or produced partial benefit. The assessment reviews symptoms, function and safety, as well as previous therapy and relevant medical conditions. Insurance criteria for a particular advanced treatment may ask for a different documented history from the clinical assessment.
Identify what changed during each medicine or therapy trial and why it ended. Pharmacy records, clinician notes and discharge summaries can help. A brief exposure stopped for intolerance is important history but is not automatically an adequate effectiveness trial.
The psychiatrist may consider optimizing the current treatment, switching or adding treatment, a suitable psychotherapy or referral for ECT or repetitive transcranial magnetic stimulation. Spravato and off-label ketamine are distinct options with different indications and safeguards. No listed option is automatically available at Nao.
Agree on which symptoms and daily activities matter, how progress will be measured and when the plan will be reconsidered. Include a safety plan, side-effect monitoring and a contact if depression worsens.
Bring the treatment timeline, current medicine list and goals for sleep, work, relationships or self-care. Explain any history of unusually high energy, much less need for sleep, impulsivity or psychosis. Include relevant substance use, pregnancy concerns and previous brain-stimulation or ketamine treatment. Ask which records are needed before an advanced-treatment assessment and which costs are associated with it.
Worsening depression, suicidal thoughts, mania or psychosis require prompt assessment. An immediate threat to safety needs emergency care. Do not stop antidepressants abruptly, combine leftover medicines or increase a dose to accelerate improvement. Every proposed option has its own contraindications and adverse effects. Spravato has monitored-visit and transport requirements. Ketamine psychiatric use is off-label. Brain stimulation has a separate specialist assessment.
Review changes in symptoms and daily function rather than relying only on an initial impression. Tell the team about side effects and missed treatment so the assessment reflects the real exposure. Partial improvement can lead to a different next step from no response or poor tolerability. A maintenance and relapse plan remains necessary after improvement.
Ask whether the visit is a diagnostic review, medication follow-up or assessment for a specific advanced treatment. Confirm referral requirements, records, benefit checks and the actual treatment site. Coverage of an evaluation does not establish coverage of ECT, TMS, Spravato or off-label infusions. Ask which advanced options are offered onsite and which need referral.
Spravato is the brand name for esketamine nasal spray. Its current US label covers treatment-resistant depression in adults, either on its own or with an oral antidepressant. A separate indication covers depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behaviour; that use requires an oral antidepressant. These indications should not be merged into one promise. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behaviour, and it does not replace hospitalization when that is needed.
Assessment reviews the diagnosis, previous treatments and whether they were taken at an adequate dose and duration. The clinician checks blood pressure, cardiovascular and cerebrovascular history, psychosis, substance-use risks, pregnancy and interacting medicines. Aneurysmal vascular disease, arteriovenous malformation, a history of intracerebral hemorrhage and hypersensitivity are labelled contraindications. Insurer criteria can differ from the clinical label.
Spravato is the brand name for esketamine nasal spray. Its current US label covers treatment-resistant depression in adults, either on its own or with an oral antidepressant. A separate indication covers depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behaviour; that use requires an oral antidepressant. These indications should not be merged into one promise. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behaviour, and it does not replace hospitalization when that is needed.
Assessment reviews the diagnosis, previous treatments and whether they were taken at an adequate dose and duration. The clinician checks blood pressure, cardiovascular and cerebrovascular history, psychosis, substance-use risks, pregnancy and interacting medicines. Aneurysmal vascular disease, arteriovenous malformation, a history of intracerebral hemorrhage and hypersensitivity are labelled contraindications. Insurer criteria can differ from the clinical label.
Esketamine affects NMDA receptors in the brain. Its antidepressant mechanism is not fully understood. It differs from standard oral antidepressants and from IV ketamine. Feeling dissociated during a session is not a test of whether the depression treatment will work. The clinician judges benefit from symptoms, daily function and safety over time.
The boxed warning covers sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviours associated with antidepressants in younger people. Do not drive, operate machinery or undertake activities requiring full alertness until the next day after a restful sleep. Arrange a ride home even if you feel ready to drive. Blood-pressure elevation can make a session unsuitable. Pregnancy may harm the fetus and breastfeeding is not recommended during treatment. Urgent worsening depression or a suicide crisis needs immediate clinical or emergency care rather than waiting for the next session.
Treatment-resistant depression describes depression that has not responded adequately to appropriate treatment trials. Definitions can differ by guideline, study and insurer. In many settings, the term involves inadequate response to at least two antidepressant trials at an adequate dose and duration. A careful review is more useful than a medicine count alone: it helps explain what was tried, why it did not help and which next step fits the person.
Bring names, doses and dates of previous treatments, including whether they were taken regularly, caused side effects or produced partial benefit. The assessment reviews symptoms, function and safety, as well as previous therapy and relevant medical conditions. Insurance criteria for a particular advanced treatment may ask for a different documented history from the clinical assessment.
Identify what changed during each medicine or therapy trial and why it ended. Pharmacy records, clinician notes and discharge summaries can help. A brief exposure stopped for intolerance is important history but is not automatically an adequate effectiveness trial.
The psychiatrist may consider optimizing the current treatment, switching or adding treatment, a suitable psychotherapy or referral for ECT or repetitive transcranial magnetic stimulation. Spravato and off-label ketamine are distinct options with different indications and safeguards. No listed option is automatically available at Nao.
Agree on which symptoms and daily activities matter, how progress will be measured and when the plan will be reconsidered. Include a safety plan, side-effect monitoring and a contact if depression worsens.
Review changes in symptoms and daily function rather than relying only on an initial impression. Tell the team about side effects and missed treatment so the assessment reflects the real exposure. Partial improvement can lead to a different next step from no response or poor tolerability. A maintenance and relapse plan remains necessary after improvement.
Treatment-resistant depression describes depression that has not responded adequately to appropriate treatment trials. Definitions can differ by guideline, study and insurer. In many settings, the term involves inadequate response to at least two antidepressant trials at an adequate dose and duration. A careful review is more useful than a medicine count alone: it helps explain what was tried, why it did not help and which next step fits the person.
Bring names, doses and dates of previous treatments, including whether they were taken regularly, caused side effects or produced partial benefit. The assessment reviews symptoms, function and safety, as well as previous therapy and relevant medical conditions. Insurance criteria for a particular advanced treatment may ask for a different documented history from the clinical assessment.
Identify what changed during each medicine or therapy trial and why it ended. Pharmacy records, clinician notes and discharge summaries can help. A brief exposure stopped for intolerance is important history but is not automatically an adequate effectiveness trial.
The psychiatrist may consider optimizing the current treatment, switching or adding treatment, a suitable psychotherapy or referral for ECT or repetitive transcranial magnetic stimulation. Spravato and off-label ketamine are distinct options with different indications and safeguards. No listed option is automatically available at Nao.
Agree on which symptoms and daily activities matter, how progress will be measured and when the plan will be reconsidered. Include a safety plan, side-effect monitoring and a contact if depression worsens.
Worsening depression, suicidal thoughts, mania or psychosis require prompt assessment. An immediate threat to safety needs emergency care. Do not stop antidepressants abruptly, combine leftover medicines or increase a dose to accelerate improvement. Every proposed option has its own contraindications and adverse effects. Spravato has monitored-visit and transport requirements. Ketamine psychiatric use is off-label. Brain stimulation has a separate specialist assessment.
Review changes in symptoms and daily function rather than relying only on an initial impression. Tell the team about side effects and missed treatment so the assessment reflects the real exposure. Partial improvement can lead to a different next step from no response or poor tolerability. A maintenance and relapse plan remains necessary after improvement.
At Nao Medical, we provide comprehensive depression treatment in New York, including advanced FDA-approved options like Spravato® (esketamine) nasal spray - a breakthrough therapy for adults with treatment-resistant or refractory depression.
A clinician can assess treatment-resistant depression and discuss whether Spravato treatments are appropriate for you. Treatment decisions depend on previous treatment, current symptoms and safety.
Enter your phone number to begin scheduling your appointment.
You will be redirected to complete the appointment booking. Next: Book Appointment
Nao Medical will never sell your information to a third party.
